A two-phase study investigating the quality of life benefit of additional 0.5% cocaine mouthwash to institutional standard of care mucositis management in head and neck cancer patients undergoing radiotherapy or chemoradiotherapy
The study was retrospectively registered with the Australian New Zealand Clinical Trials Registry (ACTRN12625000158460) on 11 February 2025.
Authors
- Joshua Dass (ORCID: https://orcid.org/0000-0002-4726-9192)
- Colin Tang (ORCID: https://orcid.org/0000-0002-4643-0466)
- Annette M. Lim (ORCID: https://orcid.org/0000-0002-0777-2279)
- Piyush Grover (ORCID: https://orcid.org/0000-0001-5717-6507)
- Elizabeth Kernutt
- Joanna Dewar (ORCID: https://orcid.org/0000-0002-1755-7097)
- Rohen White (ORCID: https://orcid.org/0000-0002-9646-3653)
- Angela Jacques (ORCID: https://orcid.org/0000-0002-0461-681X)
Institutions
- The University of Western Australia (AU)
- Peter MacCallum Cancer Centre (AU)
- Sir Charles Gairdner Hospital (AU)
- The University of Notre Dame Australia (AU)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1186/s12885-025-14955-7
- Primary Topic
- Oral health in cancer treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00